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ELISPOT assays. In order to remove these speciﬁc T cells from
the entire splenocyte population we took advantage of the PE
labeling on the LYL8 tetramer. Using anti-PE microbeads and
AUTOMACS separation, we have successfully depleted LYL8
tetramer positive T cells from both naı¨ve and immunized B6
spleens. Finally, we have been able to demonstrate that ex vivo
depletion of tetramer positive cells from naı¨ve B6 splenocytes prior
to adoptive transfer along with TCD-BM signiﬁcantly delayed the
onset of lethal GVHD post BMT (see table).
We have shown that speciﬁc depletion of antigen speciﬁc T cells
is a feasible and successful method for the elimination of GVHD in
this model.
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THERAPY FOR REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE
(AGVHD) WITH BASILIXIMAB (BAMAB) - A SELECTIVE INTERLEUKIN-2
RECEPTOR (IL-2R) ANTAGONIST
Moreira, V.A., Bonﬁm, C.M., Bitencourt, M.A., Setubal, D.C., Loren-
zato, C., Ruiz, J., Zanis-Netto, J., de Medeiros, C.R., Pasquini, R. BMT
Center-Federal University of Parana, Curitiba, PR, Brazil
BaMab is a chimeric murin-human monoclonal antibody, which
binds to the alpha chain of IL-2R found predominantly on acti-
vated cytotoxic T-cells. The IL-2 activation of RAS pathway,
which activates lymphocyte proliferation, differentiation and de-
velopment of a-GVHD, is inhibited by this drug through a com-
petitive antagonism. We report our experience with BaMab as
therapy for refractory a-GVHD after BMT. Thirty-four patients
(pts) with severe refractory a-GVHD received BaMab from de-
cember 1998 to october, 2003. The latest 21 pts were treated as
part of a prospective protocol. Because of a 7 days (d) half-life,
BaMab schedule was 40mg weekly for 2-3 doses (adults) and 20
weekly for 2-3 doses (children). Age: 2-38 years (y) (M: 13 y); Sex
M/F: 21/13. Unrelated BMT: 25 pts; related BMT: 9 pts. Cell
source: Bone marrow: 30; Cord blood: 4. Diagnosis: AML(4 pts),
ALL(4 pts), MDS(4 pts), CML(9 pts), Fanconi anemia (9 pts), AAS
(3 pts), other (1pt). All pts had a-GVHD grade III-IV, manifesting
from day 6-248 after transplant (M: 24 d), when in use of cyclo-
sporin, and refractory to association with steroids (2-5mg/kg/d) for
7 to 70 d (M: 17 d). Sites of GVHD involvement: skin: 32 pts; GI:
25 pts; liver: 23pts. The ﬁrst administration day of BaMab occurred
between 21-256 d after BMT (M: 42 d). Median follow-up was
196 d (range: 35-1847 d). Overall response rate was 82% (CR: 11
pts, PR: 17 pts). Two pts (8 %) were not evaluated due to early
death. Skin GVHD CR (complete response): 27/32 pts (84,3 %),
PR (partial response) : 4/32 (12,5 %), NR (no response) :
1/32(3,2%); GI GVHD CR: 12/25 pts (48 %), PR: 8/25 pts(32 %),
NR : 4/25(16%), NA (not available): 1/25 (4%); liver GVHD CR
: 6/23 pt (26%), PR:7/23 (30,5%), NR : 8/23 pts (34,7%), NA:
2/23(8,8). Time to ﬁrst signs of response was 1-30 d (M: 7 d).
Duration of response varied from 5-1103 d (M: 38 d). There were
no infusion-related reactions. Estimated 5 y overall survival: 32%.
Eleven (11) pts are alive, 7 pts with CR, 3 PR and 1 pt SR (with
isolated skin GVHD). Main causes of death included: disseminated
CMV (4 pt), fungal infection (6 pts), sepsis (8 pts), haemorrhage
(2pts), and relapse (2 pts with ALL). GVHD relapses were seen on
14/34 pts (41%), but 7 pts (28%) were rescued with another
therapy (MMF, PUVA, steroids). BaMab administration is safe and
this drug is useful to treat refractory a-GVHD. Prospective studies
are necessary to evaluate its optimal treatment schedule and efﬁ-
cacy.
HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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RESULTS OF THE CORD BLOOD TRANSPLANTATION STUDY (COBLT)
UNRELATED DONOR BANKING PROGRAM
Kurtzberg, J.1, Wagner, E.L.2, Fraser, J.K.3, Cairo, M.S.4, Jensen, L.2,
Cohen, G.5, Carter, S.L.5, Kernan, N.A.6 1. Duke University Medical
Center, Durham, NC; 2. National Heart, Lung, and Blood Institute,
Bethesda, MD; 3. University of California at Los Angeles, Los Angeles,
CA; 4. Georgetown University Medical Center, Washington, DC; 5.
The Emmes Corporation, Rockville, MD; 6. Memorial Sloan Kettering
Cancer Center, New York, NY
The COBLT banking program, initiated in 1996 with support
from the National Heart Lung and Blood Institute aimed to 1)
develop standard operating procedures (SOPs) for donor screen-
ing, recruitment and consenting and for collection, testing, pro-
cessing, cryopreservation, and thawing of unrelated donor umbil-
ical cord blood (UCB) and 2) build an ethnically diverse unrelated
cord blood bank to support a transplantation research protocol.
The program included multiple collection sites, 3 banks, a steering
committee and coordinating center which developed a web based
data collection system. Collections were initiated 12/97 and com-
pleted 7/2001. Screening data for 34,799 potential donors were
collected from 4/98 to 3/2001. Of these 10,599 (30%) were not
approached due to lack of informed consent or a COBLT exclu-
sion criterion. A total 20,710 mothers (60% of screened) were
approached and consented to participate in the program and UCB
was collected from 48 % of those screened and 81% of those
consented. 17,207 cord blood units (CBUs) of diverse ethnicity
were collected (40% Caucasian; 17% African-American; 11%
Asian; 20% Hispanic; 13% Mixed/Other). Of these, 11,096 (64%)
were cryopreserved and placed in quarantine. Of these, 49% passed
all eligibility criteria, were HLA-typed and entered into the
COBLT search registry. The reasons for exclusion after collection
were insufﬁcient volume or cell count (64%), a positive maternal
infectious disease test (8%) or a risk factor in the maternal history
(8%). The mean total viable nucleated, CD34, and CD3 cell
counts for the banked units were 9.2x10e8, 3.4x10e6 and 1.8x10e8,
respectively. The mean total CFU-GM count was 9.3x10e5. Rela-
tionships between ethnicity, route of delivery, birth weight, ma-
ternal age, gestational age, infant gender and UCB yields in banked
CBUs were examined. Higher cord blood volumes and total nu-
cleated cell count (TNC) were obtained from C-section compared
to vaginal deliveries. Units from African American donors con-
tained lower TNC counts per volume compared to other ethnici-
ties. UCB volume, TNC and CD34 cell content correlated with
birth weight. CD34 content decreased with increasing gesta-
tional age. The COBLT Program demonstrates that SOPs for
donor recruitment and consenting, collection, processing, cryo-
preservation, quality assurance, and data collection can be success-
fully developed and implemented in multiple banks coordinated by
a single coordinating center.
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EMBRYONIC STEM CELLS AS AN ALTERNATIVE DONOR MARROW
SOURCE: ENGRAFTMENT WITHOUT GVHD
Burt, R.K., Oyama, Y., Verda, L. Northwestern University, Chicago, IL
Hematopoietic stem cells (HSCs) have been considered unique
in their ability to reconstitute hematopoiesis following transplan-
tation into an immune compromised host. HSCs cannot be re-
newed ex vivo and must be individually collected from each donor
or patient resulting in inter-patient as well as intra-patient lot
Table. Clonal Deletion of LYL8-speciﬁc T Cells Prior to Adoptive
Transfer Signiﬁcantly Delays the Onset of GVHD
B6 Bone Marrow  N
Median
Survival
(Days)
P
Value
B6 T Cells 9 14 0.0055
LYL8- B6 T Cells 9 31
HSV8-B6 T Cells
(non-specific
control) 4 8 0.0003
*P values compare indicated group to LYL8- B6 T cells group.
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variability. In contrast, a single embryonic stem cell (ESC) line can
be repetitively cryopreserved, thawed, expanded, and differentiated
into various cellular components serving as a renewable and well-
characterized stem cell source. We, therefore, determined whether
ESCs could be used to reconstitute marrow and blood in major
histocompatibility (MHC) mismatched mice. To induce differen-
tiation toward HSC in vitro, ESCs were cultured in methylcellulose
with hematopoietic cytokines, stem cell factor (SCF), interleukin-3
(IL-3), interleukin-6 (IL-6). After 7-10 of culture, H2b ESC-
derived cytokine induced hematopoietic stem cells (c-kit/CD34)
were isolated by ﬂow cytometry and injected either intra bone
marrow (IBM) or intravenously (IV) into lethally irradiate MHC
mismatched H2d recipient mice. From two to twenty weeks after
injection, the peripheral blood demonstrated increasing donor de-
rived H2b positive mononuclear cells that included donor derived
T lymphocytes, B lymphocytes, monocytes and granulocytes with-
out clinical or histologic evidence of graft versus host disease
(GvHD). Mixed lymphocyte culture (MLC) proliferation assays
demonstrated T cell tolerance to both recipient and donor but
intact 3rd party proliferative responses and interferon-
 produc-
tion. Embryonic stem cells may be used as a renewable alternate
marrow donor source that reconstitutes hematopoiesis with intact
immune responsiveness without graft versus host disease despite
crossing MHC barriers.
IMMUNE RECONSTITUTION
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ANTI-3RD PARTY VETO CTLS DEPLETED OF HOST REACTIVE CLONES
RETAIN A BROAD TCR REPERTOIRE: A POTENTIAL NEW SOURCE FOR
ADOPTIVE IMMUNE THERAPY IN BONE MARROW TRANSPLANTATION
Aviner, S.1, Bachar-Lustig, E.1, Brouard, S.2, Goren, R.A.1, Guillet,
M.2, Soulillou, J.-P.2, Reisner, Y.1 1. Immunology, Weizmann Institute
of Science, Rehovot, Israel; 2. Institut National de la Sante et de la
Recherche Medicale, Nantes, France
CD8 cytotoxic T lymphocytes (CTLs) are endowed with a
powerful capacity to induce speciﬁc tolerance against their histo-
compatibility antigens (veto). Very recently, we developed a new
approach to deplete CTLs of host-reactive clones by stimulating
the donor T cells against 3rd party stimulators in the absence of
exogenous IL-2. It could be anticipated that this procedure, which
leads to a marked frequency reduction of anti-host clones, should
also be associated with substantial narrowing of the TCR reper-
toire, thereby limiting the use of these veto cells for tolerance
induction. In the present study we used a new technique (TcLand-
scape) which enables qualitative and quantitative analysis of V	
chain usage at the CDR3 length distribution level to compare the
repertoire of anti-3rd party CTLs to that of the original donor.
Mouse and human anti-3rd party CTLs were prepared as previ-
ously described. Mouse splenocytes of Balb/c and FVB were used
as effectors and stimulators, respectively. Human PBMC from
normal donors were stimulated against EBV transformed cell lines,
completely mismatched for HLA class1. cDNA samples obtained
from mouse and human CD8 responder T cells before (day 0)
and after initiation of culture (days 22 and 33 respectively) were
analyzed for V	 repertoire. The analysis showed that in CTLs of
both human and mice, a signiﬁcant ampliﬁcation or reduction was
evident only in particular CDR3 lengths of speciﬁc V	 families.
Thus, mouse anti-3rd party CTLs exhibit marked clonal reductions
in V	3, V	5, V	12, V	13 and V	16. Changes in the latter one
were most dramatic and it is almost oligoclonal. In contrast, only
minor alterations were found in all the other V	 families indicating
a preservation of broad repertoire. Analysis of CDR3 lengths of
anti-3rd party human CTLs showed similar preservation of broad
repertoire along with marked reduction of particular CDR3 length
clones in V	12, V	15 and V	21. These ﬁndings are of particular
relevance to BMT, as it might enable to use anti-3rd party CTLs
not only for enhancement of engraftment, but also for adoptive
transfer of immunity during the early post transplant period. Fur-
thermore, these results raise new possibilities for molecular prob-
ing of the antigens which trigger alloreactivity in mouse and in
man.
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ADOPTIVE TRANSFER OF EX VIVO COSTIMULATED AUTOLOGOUS T-
CELLS AFTER AUTOTRANSPLANTATION FOR MYELOMA (MM)ACCELER-
ATES POST-TRANSPLANT T-CELL RECOVERY
Rapoport, A.P.1, Stadtmauer, E.A.2, Levine, B.L.2, Badros, A.1, Akpek,
G.1, Cotte, J.2, Chrisley, L.1, Veloso, E.1, Westphal, S.1, Zheng, Z.2,
Grandﬁeld, K.2, Ratterree, B.1, Natt, S.1, Hinkle, J.2, Porter, D.2,
Luger, S.2, Ruehle, K.1, George, B.1, Guo, C.1, Mann, D.1, Cross, A.1,
June, C.H.2 1. University of Maryland Greenebaum Cancer Center,
Baltimore, MD; 2. Abramson Family Cancer Center, University of
Pennsylvania, Philadelphia, PA
Ex-vivo co-stimulation of autologous T-cells using anti-CD3/
anti-CD28-conjugated magnetic beads may restore T-cell respon-
siveness toward MM cells. 40 patients (pts) received ex-vivo co-
stimulated autologous T-cells after autotransplantation. The mean
age was 58 (range 43-72), 72% were male, 24% had IgA parapro-
teins, 12% had del 13 or complex karyotypes and the median 	2m
level at diagnosis was 3.32 mg/L (range 1.09-73.7). Lymphocyte
collections were followed by cyclophosphamide (4.5 g/m2) G-CSF
for stem cell mobilization melphalan (200 mg/m2 or 140 mg/m2 for
pts 70). T-cells were cultured for 12 days with anti-CD3/anti-
CD28-immobilized immunomagnetic beads & IL-2 supplementa-
tion (100 units/ml). During a run-in phase, 12 pts received T-cells
post-transplant (day 12) alone; afterwards, 28 pts participated
in a 2  2 randomization in which they received T-cells “early”
(day 12) or “late” (day 100) after transplant also received 2
immunizations with the pneumococcal conjugate vaccine (PCV,
Prevnar®) days 30 90 or 3 immunizations (prior to T-cell
collection, days 30, 90) to test immune responses. 27 pts re-
ceived 1 or more PCV immunizations and there were no grade 3/4
adverse events. Anti-pneumococcal antibody T-cell response assays
are underway for pts who completed the study. 33 pts received a
mean of 8.11  109 costimulated T-cells (range 1.6-11) all infu-
sions were well tolerated. There were no delayed adverse effects
except for grade 1-2 facial/upper body rashes in 6 pts (median 13
days after T-cells) and 1 episode of grade 2 conjunctivitis. At T-cell
harvesting, the mean % of CD3  cells in culture was 94.2% the
mean T-cell doubling level was 5.2. Among the randomized pts, at
day  42 post-transplant (30 days after T-cell infusion for the
“early” groups), the mean CD4/CD3 count was 679/l (95% CI,
347-1012) for the “early” T-cell recipients vs 278/l (95% CI,
59-497) for the “late” T-cell recipients (T-cells not yet infused)
[P  0.03]. The mean CD8/CD3 counts were 1826/l (95% CI,
1275-2376) 1105/l (95% CI, 404-1806) for the “early” and “late”
T-cell recipient respectively at day 42 [P  0.07]. 32 pts were
evaluable for clinical responses (8 are too early). There were 6 CRs,
15 VGPRs (90% reduction in paraprotein levels), 10 PRs (50-
90% reductions), 1 pt had no response. Post-transplant infusions of
ex-vivo expanded autologous T-cells are feasible and well-tolerated
may be associated with accelerated T-cell recovery.
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ACCELERATED IMMUNE RECONSTITUTION USING LLME TREATED DO-
NOR LYMPHOCYTE INFUSIONS
Filicko, J.E.1, Grosso, D.1, Flomenberg, P.1, Friedman, T.1, Brunner,
J.1, Dessain, S.1, Drobyski, W.2, Ferber, A.1, Kakhniashvili, I.1,
Keever-Taylor, C.2, Mookerjee, B.1, Wagner, J.L.1, Williams, A.1,
Korngold, R.1, Flomenberg, N.1 1. Thomas Jefferson University, Phil-
adelphia, PA; 2. Medical College of Wisconsin, Milwaukee, WI
Delayed immune reconstitution is a major cause of morbidity and
mortality after T-cell depleted allogeneic progenitor cell transplant
(PCT). To accelerate immune reconstitution without GVHD, we
have administered escalating doses of L-leucyl-L-leucine methyl
ester (LLME) treated lymphocytes (DLI) to 9 patients post
CD34 cell-enriched PCT in an ongoing phase I trial. LLME’s
cellular toxicity occurs after its polymerization by dipeptidyl pep-
tidase, leading to selective depletion of cells with cytotoxic effector
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